1Klebl BM.Advances in anti-viral therapeutics.Expert Opin Investig.Drugs,2005,14:343-348.
2Fraenkel L,McGraw S,Wongcharatrawee S,et al.Patients' experiences related to anti-viral treatment for hepatitis C.Patient Educ Couns,2006 ;62:148-155.
3Lin C,Gates CA,Rao BG,et al.In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors,VX-950 and BILN 2061.J Biol Chem,2005,280:36784-36791.
4Harper S,Avolio S,Pacini B,et al.Potent inhibitors of subgenomic hepatitis C virus RNA replication through optimization of indole-N-acetamide allosteric inhibitors of the viral NS5B polymerase.J Med Chem,2005,48:4547-4557.
5Harper S,Pacini B,Avolio S,et al.Development and preliminary optimization of indole-N-acetamide inhibitors of hepatitis C virus NS5B polymerase.J Med Chem,2005,48:1314-1317.
6Adinolfi LE,Durante-Mangoni E,Zampino R,et al.Hepatitis C virus-associated steatosis--pathogenic mechanisms and clinical implications.Aliment Pharmacol Ther,2005,22 (Suppl 2):52-55.
7Al-Traif I,Handoo FA,Al-Jumah A,et al.Chronic hepatitis C.Genotypes and response to anti-viral therapy among Saudi patients.Saudi Med J,2004,25:1935-1938.
8Muhammad N,Jan MA,Rahman N.Outcome of combined interferonribavirin in the treatment of chronic hepatitis C.J Coll Physicians Surg Pak,2004,14:651-653.
9Picardi A,Gentilucci UV,Zardi EM,et al.The role of ribavirin in the combination therapy of hepatitis C virus infection.Curr Pharm Des,2004,10:2081-2092.
10Mangia A,Spinzi G,Vuturo O,et al.Viral clearance in HCV viraemic patients with normal alanine aminotransferase after combination therapy:a controlled,open-labelled study.Aliment Pharmacol Ther,2004,19:331-337.
